
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is positioned for robust financial growth, with royalty-based income projected to increase revenues by over 20% annually through 2026 and beyond, driven by the commercial sales of Vabysmo and recent product launches. The company's total income surged to $28.5 million in 2024 from $4.8 million in 2023, fueled by increased receipts from purchased receivables and enhanced customer contracts. Looking forward, XOMA anticipates revenues of $49.0 million for 2026, representing a 36% increase from 2025, alongside potential contributions from earlier-stage assets and milestone payments, further solidifying its positive financial outlook.
Bears say
XOMA Royalty Corp has experienced significant revenue and net earnings variability, primarily influenced by fluctuations in the international market and external factors such as global economic downturns, tariffs, and changes in governmental reimbursement policies, all of which could adversely impact its operations. The potential for failed clinical trials or difficulties in securing funding for drug development further exacerbates the company's financial vulnerability, especially in light of the removal of a near-term revenue driver from its projections. Additionally, the departure of key executives could hinder the company's ability to maintain operational continuity and industry knowledge, further undermining investor confidence and contributing to stock volatility.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares